ERN Skin webinar on the EBStatMax project outcomes given by Prof. Johan Bauer and Dr. Georg Zimmermann on 30/01/2024
Bookmark this resourceResearch and Drug Development
The information and resources in this section can help you navigate in the Research and Drug Development area to identify issues classified for:
Disease models,
Disease/Translational resources,
Drug Discovery,
Clinical Development,
Advisory Committee for Therapeutics (ACT) toolkit – Agenda Template
Published by UNEW
AdviceClinical DevelopmentClinical Trial DesignPreclinical ResearchResearch and Drug DevelopmentTranslational ResearchTREAT-NMDThis agenda template can be used in conjunction with the ACT toolkit. For further information, please see the ACT toolkit.
Bookmark this resource
Advisory Committee for Therapeutics (ACT) toolkit – Applicant agreement template
Published by UNEW
AdviceClinical DevelopmentClinical Trial DesignPreclinical ResearchResearch and Drug DevelopmentTranslational ResearchTREAT-NMDThis applicant agreement template can be used in conjunction with the ACT toolkit. For further information, please see the ACT toolkit.
Bookmark this resource
Advisory Committee for Therapeutics (ACT) toolkit – Conflict of interest (CoI) form template
Published by UNEW
AdviceClinical DevelopmentClinical Trial DesignPreclinical ResearchResearch and Drug DevelopmentTranslational ResearchTREAT-NMDThis conflict of interest form template can be used in conjunction with the ACT toolkit. For further information, please see the ACT toolkit.
Bookmark this resourceBBMRI-ERIC is a European research infrastructure for biobanking. We bring together all the main players from the biobanking field – researchers, biobankers, industry, and patients – to boost biomedical research. To that end, we offer quality management services, support with ethical, legal and societal issues, and a number of online tools and software solutions. Ultimately, our goal is to make new treatments possible.
View this resource Bookmark this resourceThis article is a review of the main concepts about In silico modeling of diseases. Examples and applications of In silico modeling for some important categories of diseases (such as for cancers, infectious diseases, and neuronal diseases) are also given.
View this resource Bookmark this resourceThis website provides In silico modeling tools to measure key aspects affecting the performance of nanomedicines release. It offers physiologically-based biopharmaceutics (PBB) modeling with the aims to support the development of the novel in vitro methods.
View this resource Bookmark this resource
In Silico Model in Toxicology and Risk Assessment
Published by Frontiers Media
In silicophysiologically-based kinetic and dynamic modelQSAR modelThis article aims to address the latest developments in the area of In silico modelling and New approach methodologies (NAMs) including physiologically-based kinetic and dynamic (PBK-D) model, In silico model for the prediction of toxicological such as QSAR model and machine learning algorithms, the use of quantitative adverse outcome pathways for hazard characterisation of chemicals to cite but a few
View this resource Bookmark this resource
A European standardization framework for data integration and data-driven In Silico Model for personalized medicine – EU-STANDS4PM
Published by EU-STANDS4PM consortium
ethicalIn silicoLegalThis report therefore surveys the legal landscape for health data integration, and the challenges which arise when information is re-used to develop analytical or predictive model, which are then re-applied to a patient population
View this resource Bookmark this resource
In silico Methods for Drug Design and Discovery
Published by Computers in Biology and Medicine
In sillicomethodstoolsIn this review,is briefly introduced computational drug discovery strategies and outline up-to-date tools to perform the strategies as well as available knowledge bases for those who develop their own computational model.
View this resource Bookmark this resource